National Cancer Institute (nci)

This study tests whether a stem cell transplant can cure people with serious immune system disorders. Participants, aged 4 to 69, receive healthy donor stem cells to rebuild their immune system. The goal is to see if the transplant can permanently fix the immune defect and elimin…

This study tests whether adding the drug acalabrutinib to standard chemotherapy can help more people with untreated diffuse large B-cell lymphoma be cured. About 132 adults with this aggressive lymphoma will take acalabrutinib pills twice daily for up to 14 days, then receive sta…

This study tests a new type of focused radiation (SBRT) to cure early-stage prostate cancer that hasn't spread. Instead of treating the whole prostate, only the tumor is targeted, which may reduce side effects. About 42 men with low- or intermediate-risk prostate cancer will rece…

This early-stage trial tests a new vaccine called RG1-VLP in 18 healthy women to see if it is safe and can trigger an immune response against HPV types not covered by current vaccines. HPV is a common infection that can cause certain cancers. The goal is to find the best dose and…

This early-phase trial tests whether adding the experimental drug ipatasertib to standard chemotherapy and radiation is safe and effective for people with advanced head and neck cancer. About 46 adults with certain types of head and neck cancer will receive ipatasertib alongside …

This early-phase trial tests a new oral drug, Aza-TdC, in adults with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can turn on genes that may slow tumor growth. Participants take the drug in 21-day cycle…

This early-stage study tests the safety and best dose of combining two drugs—nivolumab and ASTX727—for people with B-cell lymphoma that has returned or stopped responding to standard treatments. Nivolumab helps the immune system attack cancer cells, while ASTX727 makes cancer cel…

This study tests whether adding palbociclib to neratinib works better than neratinib alone for people with HER2-positive gynecologic or other solid tumors (excluding breast cancer). About 70 adults with recurrent or advanced cancers will be randomly assigned to one of the two tre…

This early-phase trial tests a new drug called ADCT-701 in adults with rare neuroendocrine cancers that have not responded to standard treatments. The main goals are to find the safest dose and to see if the drug can shrink tumors or slow disease growth. Participants receive the …

This early-phase trial tests whether combining two drugs—iberdomide and teclistamab—is safe and tolerable for people with multiple myeloma that has returned or no longer responds to treatment. About 26 participants will receive the combination to find the best dose and check for …

This early-phase trial tests a new drug, ZEN003694, combined with the standard chemotherapy capecitabine in 30 adults with advanced solid tumors that have spread or cannot be removed and no longer respond to standard treatments. The main goals are to find the safest dose and unde…

This study tests whether adding a targeted drug (gilteritinib) to standard therapy (azacitidine and venetoclax) can help older or less fit adults with a specific genetic form of acute myeloid leukemia (FLT3-mutated AML) achieve deeper remission. About 147 participants will be ran…

This phase 3 trial compares a two-drug combination (osimertinib plus bevacizumab) against osimertinib alone as the first treatment for people with advanced EGFR-mutant non-small cell lung cancer. The goal is to see if adding bevacizumab helps control the cancer longer and improve…

This study tests a treatment called CAR T-cell therapy for people with advanced B-cell leukemias that haven't responded to standard drugs. Participants' own immune cells are collected, modified to recognize and attack cancer cells, and then returned to the body. The goal is to co…

This study tests whether a natural supplement called urolithin A, found in pomegranates, can reduce cell damage in prostate tumors. About 90 men with prostate cancer will take either the supplement or a placebo daily for 3 to 6 weeks before their prostate removal surgery. Researc…

This early-stage trial tests a combination of four drugs (methotrexate, rituximab, lenalidomide, and nivolumab) in people with primary CNS lymphoma, a rare type of brain cancer. The goal is to find the safest dose and see if adding lenalidomide and nivolumab can help control the …

This study compares three drug combinations for people with untreated Waldenstrom's macroglobulinemia, a rare blood cancer. About 92 participants will receive either ibrutinib plus rituximab, zanubrutinib alone, or venetoclax plus rituximab. The goal is to see which approach lead…

This study tests a personalized vaccine plus three other drugs in 60 adults with advanced HER2-positive endometrial cancer that returned after treatment. The vaccine is made from each patient's own blood cells and targets the HER2 protein. The goal is to see if this combination c…

This early-phase study tests a new treatment where a person's own immune cells are modified in a lab to better recognize and attack cancer cells that have a specific marker called GPC3. The main goal is to see if this therapy is safe for adults with advanced liver cancer or other…

This study tests whether a combination of drugs (pembrolizumab and N-803, with or without special immune cells called PD-L1 t-haNK cells) can help shrink head and neck cancers before surgery. About 40 adults with untreated, HPV-negative head and neck cancer will receive these tre…

This study tests a personalized gene therapy for people with metastatic cancers that haven't responded to standard treatments. Doctors take a patient's own white blood cells, genetically modify them in a lab to recognize and attack unique mutations in their tumor, then infuse the…

This study is for people living with HIV who also have a blood cancer that can be treated with a bone marrow transplant. Researchers want to see if a new mix of three drugs can safely prevent graft-versus-host disease, a common complication where donor cells attack the patient's …

This study tests whether adding nivolumab to blinatumomab works better than blinatumomab alone for children and young adults (ages 1 to 30) whose B-cell acute lymphoblastic leukemia (B-ALL) has returned after initial treatment. Participants include those with Down syndrome. The g…

This early-phase trial tests a combination of two targeted drugs, abemaciclib and olaparib, in people with ovarian cancer that has stopped responding to platinum-based chemotherapy. The main goal is to find the safest and most effective dose of the combination. About 42 participa…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy before surgery can help shrink high-risk liver cancer (intrahepatic cholangiocarcinoma). About 27 adults with resectable tumors will receive four cycles of the combination, then undergo sur…

This study tests whether two drugs, nilotinib and paclitaxel, can shrink or stop rare cancers that have not responded to standard treatments. About 82 adults with rare advanced cancers will take nilotinib pills twice daily and receive weekly paclitaxel infusions in 28-day cycles.…

This study tests whether hormone therapy plus a targeted drug (ribociclib) works as well as chemotherapy followed by the same hormone therapy for people with high-stage, estrogen-positive, HER2-negative breast cancer that has a low risk of coming back. About 1,978 postmenopausal …

This study compares two treatments for a type of bladder cancer that hasn't spread into the muscle. One group gets the immunotherapy drug pembrolizumab plus radiation, while the other gets standard chemotherapy plus radiation. The goal is to see which combination better prevents …

This study tests whether adding the drugs M3814 and avelumab to standard radium-223 therapy can better control advanced prostate cancer that has spread to bones. About 90 adults with castration-resistant prostate cancer will receive either radium-223 alone or with one or both add…

This study tests a new drug, ZEN003694, combined with standard chemotherapy for people with a rare and aggressive cancer called NUT carcinoma. The goal is to find the safest dose and see if the combination shrinks tumors. About 36 adults with advanced or spreading NUT carcinoma w…

This study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy (paclitaxel and ramucirumab) helps people with advanced stomach or esophageal cancer live longer without their disease getting worse. About 224 adults whose cancer has a specific marker (PD-…

This study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy (gemcitabine and cisplatin) before radiation therapy is safe and effective for children and young adults (up to age 21) with newly diagnosed nasopharyngeal carcinoma. The goal is to see if t…

This study tests whether combining two targeted drugs—sotorasib and trastuzumab deruxtecan—is safe and effective for people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. About 37 adults whose cancer has spread and who have already tried other tr…

This study tests a drug called tivozanib for people with bile duct cancer that cannot be removed by surgery and has already been treated with chemotherapy. The goal is to find the safest and most effective dose and see if it can shrink or slow the cancer. About 31 adults will tak…

This study tests whether adding venetoclax to standard chemotherapy helps more younger adults with intermediate-risk acute myeloid leukemia (AML) achieve a deep remission where no cancer cells can be detected. About 153 participants will receive either standard chemo alone, stand…

This study tests a new way to use radiation before surgery for people whose adrenal cancer has come back. The goal is to find a safe radiation dose and see if it helps shrink tumors before removal. About 32 adults with recurrent adrenal cancer that can be surgically removed will …

This early-stage trial tests whether combining two drugs—abemaciclib and 5-fluorouracil—is safe and tolerable for people with advanced colorectal cancer that has spread and no longer responds to standard treatments. About 39 adults will receive the combination to find the best do…

This study tests whether adding an immunotherapy drug (durvalumab) to standard chemotherapy can better prevent breast cancer from coming back in people with a high-risk type of hormone receptor-positive, HER2-negative breast cancer. About 3,680 adults with stage II or III breast …

This study tests a drug called binimetinib for people with hairy cell leukemia that lacks the usual BRAF gene mutation. About 40 adults whose leukemia returned or didn't respond to prior treatment will take the pill twice daily. The goal is to see if blocking the MEK protein can …

This study tests whether giving donor white blood cells (lymphocytes) soon after a stem cell transplant can lower the chance of cancer returning in people with high-risk blood cancers like leukemia or lymphoma. Participants receive chemotherapy, a stem cell transplant, and then a…

This study tests a new treatment for children and young adults (ages 3-39) with B-cell leukemia or lymphoma that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to target two cancer proteins (CD19 …

This study tests whether a combination of three drugs—bevacizumab, erlotinib, and atezolizumab—can shrink or stabilize advanced kidney cancer in people with a rare inherited form (HLRCC) or sporadic papillary kidney cancer. About 65 adults with measurable tumors will receive the …

This early-phase study tests whether a new type of immunotherapy, called anti-CD22 CAR T cells, is safe for people with hairy cell leukemia (HCL) that has come back or not responded to standard treatments. Up to 27 adults will have their own immune cells collected, modified in a …

This study tests whether adding an injected drug (PDS01ADC) to a daily pill (enzalutamide) can better control PSA levels in men whose prostate cancer has returned after initial treatment. About 65 participants will receive either enzalutamide alone or both drugs for 3 months, wit…

This study tests a combination of two drugs, temozolomide and M1774, in people with advanced or metastatic solid tumors. The goal is to find the best dose and see if the combo can shrink tumors or keep them from growing longer than temozolomide alone. About 42 adults with certain…

This study tests a combination of three drugs (cabozantinib, nivolumab, and ipilimumab) in people with rare genitourinary cancers that have spread. The goal is to see if the combination shrinks tumors better than any single drug. About 314 adults with these rare cancers are being…

This study tests a drug called pacritinib in people aged 12 and older with myelodysplastic syndromes (MDS) or related blood cancers. The goal is to find the best dose and see if it can shrink or control the disease. Participants take capsules twice daily for up to 8 years, with r…

This early-stage study tests a new drug called TAK-243 in about 95 adults with advanced solid tumors or lymphoma that has not responded to standard treatments. The main goal is to find the safest dose and understand side effects. TAK-243 works by blocking a protein that cancer ce…

This study tests whether adding an immunotherapy drug (atezolizumab) to standard chemotherapy works better than chemotherapy alone for people with peritoneal mesothelioma, a rare cancer of the abdominal lining. About 66 participants will receive either the usual treatment (carbop…

This study tests imatinib, a pill taken daily, in adults with a RUNX1 gene mutation that causes easy bleeding and a higher risk of blood cancers. The goal is to find the best dose and see if it improves platelet function and reduces inflammation. Participants take the drug for up…

This study tests a lab-made protein called CYT107 in 55 adults with HIV and Kaposi sarcoma (a skin cancer). The protein aims to boost the immune system by increasing T cells, which may help shrink tumors. Participants receive weekly injections for up to 4 weeks, with possible rep…

This study tests a new treatment for people with certain advanced cancers (like pancreatic, stomach, or colon cancer) that have a specific genetic change called KRAS G12V. The treatment involves taking a patient's own white blood cells, modifying them in a lab to better recognize…

This early-stage trial tests the safety and best dose of two experimental drugs (M1774 and ZEN-3694) given together for ovarian and endometrial cancers that have returned after treatment. The study enrolls about 65 adults whose cancers have specific genetic features. The goal is …

This study tests whether adjusting the dose of the cancer drug belinostat based on a person's genes can make treatment safer and more effective for people with high-grade neuroendocrine carcinomas. About 60 adults will receive belinostat along with two other chemotherapy drugs. T…

This study tests whether a second round of targeted radiation therapy (177Lu-DOTATATE) works better than standard drugs (everolimus, sunitinib, or cabozantinib) for people with advanced neuroendocrine tumors of the digestive system that have spread and cannot be removed by surger…

This study tests whether adding the drug cabozantinib to standard chemotherapy works better than chemo alone for people under 40 with newly diagnosed osteosarcoma, a type of bone cancer. Cabozantinib blocks signals that help tumors grow and form blood vessels. The trial involves …

This study tests if a targeted drug called selumetinib works as well as standard chemotherapy (carboplatin and vincristine) for children and young adults with a slow-growing brain tumor called low-grade glioma. Participants must be 2 to 21 years old and have a tumor without a spe…

This study is for people who have both an autoimmune disease (like rheumatoid arthritis, lupus, or multiple sclerosis) and an advanced cancer that has spread or cannot be removed by surgery. It tests the safety and effectiveness of the immunotherapy drug nivolumab, given alone or…

This study tests whether a newer drug, mosunetuzumab, works better than the standard drug rituximab for people with a rare type of Hodgkin lymphoma called NLPHL. About 70 participants will receive one of the two treatments. The goal is to see which drug helps patients live longer…

This early-phase study tests whether adding an experimental drug (ASTX727) to standard chemotherapy and immunotherapy can safely shrink or stabilize tumors in people with metastatic triple-negative breast cancer that cannot be removed by surgery. About 32 adults will take part to…

This early study tests a new pill called pidnarulex in 40 people with advanced solid tumors that have spread and stopped responding to standard treatments. The drug blocks a key enzyme cancer cells need to divide and repair their DNA, which may kill them. Researchers will check s…

This phase 3 trial tests whether mosunetuzumab works better than rituximab for people with a slow-growing type of lymphoma that has not spread much. Both drugs are lab-made antibodies that help the immune system attack cancer cells. About 600 adults with low tumor burden follicul…

This study is for adults with advanced cancers like lung, liver, or melanoma who are eligible for the immunotherapy drug atezolizumab. Researchers want to see if giving a lower dose less often can still keep the drug at effective levels in the blood, potentially reducing side eff…

This study tests whether combining two drugs—pembrolizumab (an immunotherapy) and aldesleukin (a cytokine)—can shrink tumors in people with advanced melanoma or kidney cancer that has not responded to prior treatments. About 78 adults will receive the drugs through an IV during t…

This study tests whether adding the drug pembrolizumab to a treatment that uses a patient's own immune cells (called TIL therapy) can shrink tumors in people with advanced melanoma. About 53 adults aged 18 to 72 who have already tried at least one other treatment will take part. …

This phase 1 trial tests the safety and best dose of an oral drug called ASTX727 (a combination of cedazuridine and decitabine) given with filgrastim (a white blood cell booster) as maintenance therapy for children with high-risk acute myeloid leukemia (AML) that has returned or …

This study tests a shorter, more intense radiation schedule for people whose glioblastoma (a severe brain cancer) has returned after standard treatment. About 28 adults with recurrent grade 4 glioblastoma will receive radiation 4 times a week for 1 to 3 weeks. The goal is to find…

This study tests whether adding targeted drugs (trastuzumab and pertuzumab) to standard chemotherapy can shrink tumors and stop HER2-positive endometrial cancer from coming back. About 360 people with stage I-IV endometrial cancer will receive either chemo alone or chemo plus the…

This study tests a combination of two immunotherapy drugs (nivolumab and ipilimumab) along with two anti-rejection medications (sirolimus and prednisone) in kidney transplant recipients who have advanced skin cancer that cannot be surgically removed or has spread. The goal is to …

This early-phase study tests whether adding two inhaled antibiotics (aztreonam and vancomycin) to the standard cancer drug pembrolizumab is safe and doable for people with advanced non-small cell lung cancer. About 23 adults whose cancer has returned or progressed after prior tre…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy before surgery helps shrink tumors in people with high-grade upper urinary tract cancer. About 131 adults will be randomly assigned to receive either chemo alone or chemo plus durvalumab be…

This study tests a pill called venetoclax for people whose hairy cell leukemia has returned after prior treatment. The drug blocks a protein that cancer cells need to survive. About 20 adults will take venetoclax to see if it shrinks tumors and improves blood counts, with the goa…

This study tests a drug called tovorafenib in children and young adults (ages 6 months to under 22 years) whose Langerhans cell histiocytosis has returned or not responded to prior treatment. The drug works by blocking certain enzymes that help cancer cells grow. The trial aims t…

This study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy can help control advanced solid tumors that have spread. About 115 adults whose cancer has worsened after at least one prior treatment will receive the combination. The main goal is to chec…

This study tests a drug called selinexor combined with standard radiation for children and young adults with newly diagnosed aggressive brain tumors (DIPG or H3 K27M-mutant high-grade glioma). The goal is to find the safest dose and see if the combination helps shrink tumors or i…

This study tests two drugs, cabozantinib and nivolumab, in people with advanced melanoma or head and neck cancer that has spread. The goal is to see if the combination can shrink or stabilize tumors, and whether certain biomarkers in the tumor can predict who responds best. About…

This study tests the drug abemaciclib in people aged 12 and older with NF1 who have atypical neurofibromas that cannot be surgically removed. The goal is to find a safe dose and see if the drug can shrink or stabilize these nerve tumors. Participants take the drug twice daily for…

This study tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy helps people with a rare, aggressive type of neuroendocrine cancer that started outside the lungs. About 189 adults with advanced or metastatic disease will receive either chemo alone or …

This study tests a drug called daratumumab in people with three rare and aggressive blood cancers (primary effusion lymphoma, plasmablastic lymphoma, and multicentric Castleman disease) that have not responded to standard therapy. The drug is given as a weekly injection under the…

This study tests whether combining two drugs, Lutathera and Olaparib, can shrink neuroendocrine tumors in the pancreas or intestine that cannot be removed by surgery. About 56 adults will receive Lutathera by IV every 8 weeks and take Olaparib pills twice daily. The goal is to fi…

This study tests a drug called PT-112 in people with thymoma or thymic carcinoma that has come back or not responded to standard treatment. The goal is to see if PT-112 can shrink tumors. About 53 adults will receive the drug by infusion every few weeks for up to 8 years, as long…

This study looks at whether starting treatment early with two drugs (venetoclax and obinutuzumab) improves survival and quality of life for people newly diagnosed with high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma who do not yet have symptoms. About 247 par…

This study tests a procedure called TULSA that uses MRI images to guide high-energy ultrasound waves to destroy prostate cancer tumors. About 21 adults with early-stage prostate cancer that shows up on MRI will receive this heat-based treatment. The goal is to see if the approach…

This study tests a stem cell transplant to control peripheral T-cell lymphoma in people whose cancer has not responded to standard treatments. Participants receive a donor's stem cells after chemotherapy or antibody therapy to prepare their body. The goal is to see if this approa…

This study tests whether a second type of CAR T-cell therapy, targeting CD22, can keep acute lymphoblastic leukemia (ALL) from coming back in people who already had CD19 CAR T-cell treatment. About 20 children and adults aged 3 to 65 who show no signs of cancer after their first …

This early-phase trial tests a drug called novobiocin in people with advanced solid tumors that have specific DNA repair gene mutations (like BRCA). Novobiocin blocks a protein that cancer cells use to fix their damaged DNA, causing them to die. The study aims to find the safest …

This study tests a daily pill called enasidenib for people with rare cancers of the nasal cavity or skull base that have a specific IDH2 gene mutation. The drug aims to slow or stop tumor growth in cancers that have spread or come back after other treatments. About 40 adults with…

This study tests whether adding enasidenib to standard treatment (ASTX727) improves outcomes for people with a high-risk form of myelodysplastic syndrome (MDS) that has a specific gene mutation (IDH2). About 54 adults who have not had prior cancer therapy will be randomly assigne…

This study is testing a daily pill called talazoparib in people with advanced solid tumors (like breast, prostate, ovarian, or pancreatic cancer) that have specific DNA repair gene mutations. The drug works by blocking a protein that helps cancer cells fix their DNA, causing them…

This study tests whether adding the targeted drug cabozantinib to standard immunotherapy (nivolumab and ipilimumab) can help shrink or stabilize advanced nasopharyngeal cancer that has returned or spread. About 50 adults whose cancer worsened after platinum chemotherapy and immun…

This study tests a new approach for people with aggressive blood cancers that have not responded well to standard treatments. It combines two powerful therapies: a half-matched bone marrow transplant and specially engineered CAR T-cells that target a protein called CD19 on cancer…

This study tests whether adding the experimental drug TRC102 to standard treatment (chemotherapy, radiation, and immunotherapy) can help shrink tumors and extend survival in people with stage III non-squamous lung cancer. TRC102 blocks cancer cells from repairing damage, making t…

This study tests an oral drug called mirdametinib in about 20 adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has returned or not responded to prior therapy. The drug blocks a protein that helps cancer cells grow. The main goal is to see ho…

This study tests an experimental drug called TPST-1495 in 38 people with familial adenomatous polyposis (FAP), an inherited condition that causes many polyps in the colon and small bowel and raises colon cancer risk. The drug works by blocking certain receptors linked to polyp gr…

This early-stage trial tests whether adding the drug pomalidomide to standard chemotherapy (with or without rituximab) is safe and effective for people with HIV who have aggressive B-cell non-Hodgkin lymphoma. About 25 adults with high-risk features will receive up to 6 cycles of…

This study tests a drug called PLX038 in adults with brain or spinal cord tumors, especially those with changes in the MYC or MYCN genes. About 146 people will receive the drug through an IV every 3 weeks for up to 7 months, along with a second drug to prevent infection. The goal…

This study tests whether adding venetoclax to standard chemotherapy works as well as or better than adding gemtuzumab for people with core binding factor acute myeloid leukemia (CBF-AML). About 162 younger adults newly diagnosed with this leukemia will be randomly assigned to one…

This study is for children and young adults with a specific type of leukemia (Ph+ or Ph-like B-ALL). It combines standard chemotherapy with two newer drugs: blinatumomab, which helps the immune system attack cancer cells, and a tyrosine kinase inhibitor (dasatinib or imatinib) th…

This study tests if a stem cell transplant from a healthy donor can help people aged 4 to 75 with severe immune system disorders. Participants receive chemotherapy and then donor stem cells, followed by a hospital stay and long-term monitoring. The goal is to see if the transplan…

This early-stage trial tests a new drug called metarrestin in people with solid tumors that have spread. The goal is to find a safe dose and see if it can shrink tumors or stop them from growing further. Adults with certain cancers and children aged 12-17 with solid tumors may jo…

This study compares standard radiation plus cisplatin to two experimental combinations—radiation with docetaxel and cetuximab, or radiation with cisplatin and atezolizumab—after surgery for high-risk stage III-IV head and neck cancer. About 613 participants will be enrolled to se…

This early-phase trial tests whether adding an experimental drug (ZEN003694) to standard immunotherapy (pembrolizumab) and chemotherapy (nab-paclitaxel) is safe and tolerable for people with advanced triple-negative breast cancer that has spread. About 57 participants will receiv…

This early-stage trial tests whether combining two targeted therapies—sunitinib and a radioactive drug called Lutathera—is safe and effective for people with advanced pancreatic neuroendocrine tumors. About 24 participants will receive the combination to find the best dose and ch…

This study is for people with a type of sinus cancer called sinonasal squamous cell carcinoma. It compares standard chemotherapy before surgery to chemotherapy plus an immunotherapy drug called cemiplimab. The goal is to see if adding immunotherapy helps shrink tumors more and im…

This study tests a radioactive drug called Lu-177-DOTATATE in people with rare tumors (pheochromocytoma or paraganglioma) that cannot be removed by surgery. The goal is to see if the drug can slow or stop tumor growth and to check its safety. About 130 adults will receive four do…

This early-phase trial tests whether adding pidnarulex to the targeted therapy trastuzumab deruxtecan is safe and effective for people with advanced HER2-expressing breast cancer or other solid tumors that have spread or can't be removed. About 36 adults whose cancer has stopped …

This study is for people with stage II to IIIB non-small cell lung cancer that has been surgically removed. It tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy can help keep the cancer from coming back and extend survival. About 1,210 participant…

This study tests a two-step treatment for a type of leukemia (B-ALL) in older adults or those whose cancer came back or didn't respond to prior therapy. The drugs, inotuzumab ozogamicin and blinatumomab, work like smart bombs to target and kill cancer cells. The goal is to see if…

This early-phase trial tests a new treatment for children and young adults (ages 3–39) with rhabdomyosarcoma that has come back or not responded to at least two prior treatments. The therapy uses the patient's own immune cells, modified in a lab to better recognize and attack can…

This study tests whether adding an experimental drug (CDX-1140) to a standard immunotherapy (cemiplimab) before surgery can shrink advanced head and neck cancers more than the immunotherapy alone. About 44 people with stage III-IV head and neck cancer will receive either the comb…

This study tests whether adding the drug dinutuximab to standard chemotherapy and other treatments helps children with high-risk neuroblastoma live longer without their cancer returning. About 478 children and young adults up to age 30 will be randomly assigned to receive either …

This early-phase trial tests a new drug (rhIL-15) combined with three standard cancer drugs for children and young adults (ages 3–35) whose neuroblastoma did not respond to treatment or returned. The main goal is to find a safe dose and check for side effects. Up to 40 participan…

This study tests whether adding a personalized vaccine (made from unique tumor proteins) to a standard chemo-immunotherapy combination can help control metastatic triple-negative breast cancer better than chemo-immunotherapy alone. About 70 adults with this aggressive, advanced c…

This study tests whether a stem cell transplant from a healthy donor can control or reverse VEXAS syndrome, a rare and severe autoinflammatory disease. About 54 adults aged 18-75 whose standard treatments have failed will receive donor stem cells after chemotherapy and possibly r…

This early-stage trial tests a drug called camonsertib combined with precise radiation for head and neck cancer that has returned or cannot be surgically removed. The study aims to find the safest dose and see if the combination can control tumor growth. About 39 adults with cert…

This study tests a drug called erdafitinib in 30 adults with a specific type of brain tumor (glioma) that has returned or is growing. The tumor must have a particular gene change (FGFR-TACC fusion) and not have another common mutation (IDH-wild type). Erdafitinib works by blockin…

This study tests whether adding an experimental vaccine (PRGN-2009) to standard chemotherapy can improve outcomes for people with newly diagnosed HPV-related throat cancer. About 70 adults will receive either chemo alone or chemo plus the vaccine, followed by surgery. The goal is…

This study tests a drug called pacritinib in people with HIV who have two rare conditions caused by the Kaposi sarcoma herpesvirus (KSHV): KSHV-associated multicentric Castleman disease (MCD) and KSHV inflammatory cytokine syndrome (KICS). These conditions cause severe, life-thre…

This study tests a drug called abemaciclib, already used for breast cancer, in people with Kaposi sarcoma (KS) — both those with and without HIV. The goal is to find a safe dose and see if it can shrink KS lesions or tumors. About 111 adults aged 18 and older with KS will take th…

This study is for women whose ovarian or endometrial cancer has returned or not gone away and has a specific change in the RAS gene. It compares taking two drugs (selumetinib and olaparib) versus one drug (selumetinib alone) to see if the combination works better at shrinking tum…

This study tests a drug called M3814 combined with a special type of radiation for people with locally advanced pancreatic cancer (cancer that has spread nearby but not to distant organs). The goal is to find the safest dose and see if the combination helps stop tumor growth long…

This study tests whether the drug nivolumab can slow or stop the growth of certain cancers linked to the Epstein-Barr virus. About 40 people aged 12 and older with these cancers who have no standard treatment options will receive nivolumab every two weeks. The goal is to see if t…

This study tests whether adding the experimental drug iadademstat to standard immunotherapy (atezolizumab or durvalumab) can help keep extensive-stage small cell lung cancer under control longer. About 45 adults whose cancer responded to initial chemo-immunotherapy will participa…

This early-stage trial tests a drug called triapine combined with radiation therapy for people whose glioblastoma or astrocytoma has returned. Triapine blocks enzymes that help cancer cells grow, while radiation kills tumor cells. The study enrolls 30 adults and aims to find the …

This study tests two drugs, glofitamab and obinutuzumab, in 20 people with mantle cell lymphoma that came back or didn't respond after CAR T-cell therapy. Glofitamab helps the immune system attack cancer cells, while obinutuzumab blocks cancer growth. The goal is to see if this c…

This study tests two drugs, sapanisertib and cabozantinib, together in people with advanced liver cancer that has a specific change in the β-catenin gene. The goal is to find the best dose and see if the combination can shrink tumors or slow the cancer's growth. About 92 adults w…

This study tests a combination of up to 4 experimental drugs (retifanlimab, TriAdeno vaccine, N-803, and SX-682) in people with metastatic colorectal cancer that has spread and not responded to prior treatments. The goal is to see if this immunotherapy mix can shrink tumors and i…

This study tests whether a chemotherapy drug (sacituzumab govitecan) alone or with an immunotherapy (atezolizumab) can shrink rare cancers of the bladder, kidney, ureters, or penis. About 60 adults with advanced tumors that cannot be removed by surgery will receive treatment for …

This study tests two non-chemotherapy drugs, PDS01ADC and M7824, in people with advanced Kaposi sarcoma (KS). The drugs work by helping the immune system recognize and attack KS tumors. About 80 adults aged 18 and older whose KS has not responded well to prior treatment will rece…

This study compares the immunotherapy drug pembrolizumab to the usual chemotherapy plus radiation after surgery for head and neck cancer that has returned or is a new primary tumor. About 188 adults aged 18-79 with high-risk features (like cancer at the surgical edge or spread to…

This study tests a new combination of drugs (tovorafenib and rituximab) for people with hairy cell leukemia, a rare blood cancer. It includes two parts: one for patients whose cancer returned or didn't respond to prior treatment, and another for newly diagnosed patients comparing…

This study tests whether adding the immunotherapy drug pembrolizumab to radiation therapy after chemotherapy can help people with muscle invasive bladder cancer keep their bladder instead of having it surgically removed. About 111 adults whose tumors shrank enough after chemo wil…

This early-phase trial tests whether adding an experimental drug (CA-4948) to the immunotherapy pembrolizumab can help people with advanced bladder cancer whose tumors stopped responding to standard immunotherapy. About 27 adults with metastatic or unresectable urothelial cancer …

This early-stage trial tests whether adding the experimental drug CA-4948 to standard chemotherapy (FOLFOX) and bevacizumab is safe and tolerable for people with colorectal cancer that has spread. About 24 adults with advanced, inoperable disease will receive the combination to f…

This study tests a new two-drug treatment for people with advanced soft tissue sarcomas (cancers of the muscles, fat, or other connective tissues). The drugs, abemaciclib and gemcitabine, work together to stop cancer cells from growing. The trial will compare this new combo to th…

This study tests two cancer drugs, lurbinectedin and avelumab, in people with a rare and fast-growing bladder cancer called small cell carcinoma. About 45 adults whose cancer has spread after prior treatment will receive the drugs every three weeks for up to 10 years. The goal is…

This study tests an experimental cell therapy for advanced non-small cell lung cancer. Doctors take immune cells from a patient's tumor, grow them in large numbers, and give them back to the patient to fight the cancer. The goal is to see if this treatment can shrink tumors and h…

This study tests whether adding an immunotherapy drug (cemiplimab) to a standard cancer pill (cabozantinib) works better than the pill alone for people with advanced adrenocortical cancer that cannot be removed by surgery or has spread. About 48 adolescents and adults will take p…

This study is for people with extensive-stage small cell lung cancer who have already responded to initial chemotherapy plus the immunotherapy drug atezolizumab. It compares the usual maintenance therapy with atezolizumab alone versus atezolizumab plus targeted radiation therapy.…

This study tests whether adding a second immunotherapy drug (relatlimab) to the standard immunotherapy (nivolumab) can help keep nasopharyngeal cancer from growing or spreading for a longer time. About 156 people with recurrent or metastatic Epstein-Barr virus-associated nasophar…

This early-phase trial tests a new drug that delivers radiation directly to cancer cells with a specific protein (somatostatin receptor). It is for adults with advanced cancers of the digestive tract, adrenal glands, lung, kidney, head, or neck that cannot be removed by surgery. …

This study tests whether adding chemotherapy or a chemo-immunotherapy combination before salvage surgery can improve outcomes for people with head and neck cancer that has returned or persisted. About 180 participants with PD-L1 positive tumors will receive either standard surger…

This study tests a new treatment for people with certain blood cancers, like leukemia. Doctors take a person's own immune cells (T cells), modify them in a lab to recognize unique markers on their cancer cells, and then give them back. The goal is to see if this personalized appr…

This study tests a new drug that delivers radiation directly to cancer cells in people with advanced gastrointestinal neuroendocrine tumors or pheochromocytoma/paraganglioma. The drug works by attaching to a protein found on these tumors and then killing them with radiation. Abou…

This study tests a drug called pacritinib for people with moderate to severe chronic graft-versus-host disease (cGVHD) that hasn't responded to at least two prior treatments. cGVHD is an immune system problem that can occur after a stem cell transplant, causing damage to multiple…

This study tests whether the immunotherapy drug durvalumab, given after surgery, can help prevent early-stage non-small cell lung cancer from returning. About 306 people who have had their lung cancer completely removed will either receive durvalumab or be watched closely (standa…

This study tests whether adding an experimental drug (PDS01ADC) to standard chemotherapy (docetaxel) can help men whose prostate cancer has spread. About 86 men with either castration-sensitive or castration-resistant cancer will receive treatment in 21-day cycles. The goal is to…

This study tests an experimental treatment for people with advanced cancers (like colorectal, pancreatic, breast, or ovarian) that have spread and stopped responding to standard therapy. Doctors take white blood cells from a tumor, grow the most powerful ones in a lab, and give t…

This early-phase study tests CBX-12 in about 35 adults with advanced solid tumors that have spread and stopped responding to prior treatments. CBX-12 works by entering cancer cells and damaging their DNA, which can kill the cells. Researchers will measure how well the drug trigge…

This early-phase study tests two drugs—DS-8201a and olaparib—together in people with advanced HER2-positive cancers that have spread or can't be removed. The goal is to find the best dose and see if the combination can shrink or stabilize tumors. About 55 adults with certain soli…

This study tests whether adding a targeted chemotherapy drug (sacituzumab govitecan) to an immunotherapy (pembrolizumab) helps people with advanced bladder cancer that no longer responds to standard immunotherapy. About 320 adults with locally advanced or metastatic urothelial ca…

This study tests whether adding chemotherapy to immunotherapy (pembrolizumab) helps older adults (70+) with advanced non-small cell lung cancer live longer compared to immunotherapy alone. The trial enrolls 304 participants with stage IIIB-IV cancer and a specific PD-L1 level. Th…

This study tests whether three antibody-drug conjugates (ADCs) can shrink advanced solid tumors that have high levels of specific proteins (Trop-2, nectin-4, or HER2). About 500 adults with cancers that have spread and no longer respond to standard treatments will receive a drug …

This study is for adults aged 18-85 with blood cancers that haven't responded well to standard treatments. It tests whether a lower dose of the drug cyclophosphamide, given after a bone marrow transplant, can reduce side effects while still preventing graft-versus-host disease (a…

This study is for people with blood cancers like leukemia or lymphoma who need a stem cell transplant from a donor. After transplant, a drug called cyclophosphamide is given to prevent graft-versus-host disease, a serious side effect. Researchers want to find the lowest effective…

This study compares three treatment combinations for people with advanced or recurrent endometrial cancer that has specific genetic features (pMMR and TP53 mutated). Participants will receive either standard chemotherapy (carboplatin and paclitaxel) plus the immunotherapy pembrol…

This study tests a drug called pidnarulex (CX-5461) in 50 people with aggressive B-cell lymphomas that have MYC gene changes. The goal is to find a safe dose and see if it can shrink tumors. Participants have already tried other treatments and have few options left.

This early-phase trial tests two experimental drugs, peposertib and tuvusertib, together in adults with advanced solid tumors that have spread or cannot be removed. The main goals are to find the safest dose and understand side effects. About 66 participants will take part. This …

This study tests two drugs, palbociclib (a pill) and sasanlimab (an injection), in people with advanced kidney cancer (clear cell or papillary type). The goal is to see if the combination can shrink tumors or stop them from growing. About 100 adults who have already tried other t…

This early-phase trial tests a combination of three drugs (mosunetuzumab, polatuzumab vedotin, and lenalidomide) in about 30 adults whose diffuse large B-cell lymphoma has returned or not responded to prior treatment. The main goal is to find the safest dose and check for side ef…

This study tests a combination of five drugs (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, called ViPOR) in adults with B-cell lymphoma that has come back or not responded to prior treatment. The main goal is to check the safety of this drug mix. Up to 155 p…

This study is for people with early-stage non-small cell lung cancer that can be removed with surgery. Researchers want to see if adding an inhaled form of the drug azacytidine to standard chemotherapy and immunotherapy can help kill more cancer cells before surgery. The trial wi…

This study is for adults aged 59 or younger with a high-risk form of acute myeloid leukemia (AML) that is harder to treat. It compares the standard two-drug chemotherapy to four newer treatment combinations, including targeted drugs like venetoclax. The goal is to see which appro…

This study tests a new drug, selinexor, combined with standard chemotherapy (temozolomide) for people with glioblastoma that has returned after initial treatment. The goal is to see if the combination is safer and works better than chemo alone. About 97 adults with a specific typ…

This study tests a combination of five drugs (venetoclax, ibrutinib, prednisone, obinutuzumab, and Revlimid, called ViPOR) in people with certain aggressive lymphomas that have come back or not responded to prior therapy. The goal is to see how many patients achieve complete remi…

This study tests whether adding cetuximab to standard immunotherapy (pembrolizumab) helps people with advanced head and neck cancer that has stopped responding to platinum chemotherapy live longer. About 158 adults with cancer that has returned or spread will receive either pembr…

This study tests whether a combination of two pills (encorafenib and binimetinib) works better than the current drug for hairy cell leukemia that didn't respond to or returned after treatment. About 45 adults with a specific gene mutation (BRAF V600) will take the drugs daily in …

This study tests if a radioactive drug called lutetium Lu 177 dotatate works better than the usual drug everolimus for people with advanced bronchial neuroendocrine tumors (a type of lung cancer). The radioactive drug targets and kills tumor cells by binding to a protein on their…

This study tests whether adding two immunotherapy drugs (brentuximab vedotin and nivolumab) to standard chemotherapy and radiation helps people with early-stage Hodgkin lymphoma live longer with fewer side effects. About 1,875 people aged 5 to 60 with newly diagnosed stage I or I…

This study compares two immunotherapy drugs (nivolumab and ipilimumab) against nivolumab alone in people with recurrent endometrial cancer that has a specific DNA repair defect (dMMR). The goal is to see if the combination shrinks tumors better. About 81 participants will receive…

This study tests whether adding a round of chemotherapy and the immunotherapy drug pembrolizumab before the usual chemoradiation can help people with high-risk, locally advanced cervical cancer live longer without the disease getting worse. About 336 participants will be randomly…

This early-phase trial tests whether combining the experimental drug peposertib with a low-dose form of chemotherapy (liposomal doxorubicin) is safe and effective for people with advanced sarcomas that have spread or cannot be removed by surgery. About 30 adults with specific sar…

This early-phase trial tests whether a patient's own immune cells, modified in a lab to recognize and attack a protein called CCR4 on cancer cells, can safely treat certain types of T-cell lymphoma that have not responded to standard therapy. About 60 adults with relapsed or refr…

This study tests a new drug (CDX-1140) plus three standard cancer drugs (capecitabine, oxaliplatin, and Keytruda) in people with advanced biliary tract cancer that has worsened after prior treatment. About 60 adults will receive the drugs in 21-day cycles for up to 2 years, with …

This study tests whether a daily pill called olaparib can help keep pancreatic cancer from coming back after surgery and chemotherapy. It is for people whose tumors have specific gene mutations (BRCA1, BRCA2, or PALB2). About 152 participants will receive either olaparib or a pla…

This study tests whether a stem cell transplant from a healthy donor can treat GATA2 deficiency, a rare genetic condition that weakens the immune system and raises the risk of leukemia. Participants aged 6 to 70 receive chemotherapy or radiation before the transplant to prepare t…

This study tests whether a combination of two drugs (ZEN003694 and talazoparib) can shrink tumors in people with advanced solid cancers that have stopped responding to standard treatments. About 88 adults will take part. Researchers will also look at participants' genes to see if…

This study tests a new treatment for adults with certain cancers (pancreatic, kidney, breast, melanoma, or ovarian) that have a protein called CD70. Doctors take a sample of your blood, modify your white blood cells in a lab to recognize and attack CD70, and then give them back t…

This study tests whether adding two targeted drugs, blinatumomab and venetoclax, to standard chemotherapy can improve outcomes for infants with a type of leukemia called acute lymphoblastic leukemia (ALL). About 153 infants will participate. The goal is to see if these combinatio…

This study tests a pill called osimertinib in people with advanced lung cancer that has a specific genetic change (EGFR exon 20 insertion). The drug works by blocking signals that help cancer cells grow. About 46 participants will take the pill daily to see if it shrinks tumors o…

This early-phase study tests the safety and best dose of two drugs, ZEN003694 and abemaciclib, given together. It is for people with advanced breast cancer, NUT carcinoma, or other solid tumors that have spread or cannot be removed by surgery. The goal is to see if the combinatio…

This early-phase study tests a combination of two drugs, pomalidomide (a pill) and nivolumab (an infusion), for adults with cancers caused by viruses like Epstein-Barr, HPV, or hepatitis. The goal is to find a safe dose and see if the drugs shrink tumors. Up to 58 participants, i…

This study tests whether adding an immune-boosting drug (PDS01ADC) to standard chemotherapy delivered directly to the liver via a pump can shrink tumors in people with certain cancers that have spread to the liver. About 70 adults with metastatic colorectal cancer, bile duct canc…

This study tests two experimental drugs, ZEN003694 and entinostat, in people with advanced solid tumors that have stopped responding to standard treatments, including pancreatic cancer. The goal is to find the safest dose and see if the combination can shrink tumors. About 49 par…

This study tests a drug called TURALIO (pexidartinib) in people aged 3 to 35 whose leukemia or solid tumors have not responded to standard treatments. The goal is to find a safe dose and see if it can shrink tumors or stop them from growing. Participants take the drug daily for u…

This study tests an oral drug, zotiraciclib, for people whose brain tumors (gliomas) have come back after treatment and carry IDH1 or IDH2 mutations. About 96 participants aged 15 and older will take the drug at home on a set schedule over 28-day cycles. The goal is to see if the…

This study tests two drugs, pidnarulex and cemiplimab, in people with advanced colorectal cancer that hasn't responded to standard treatments. The goal is to find the best dose and see if the combination can slow or stop cancer growth. About 86 adults with a specific type of colo…

This early-phase study tests a combination of two drugs—trastuzumab deruxtecan and azenosertib—in people with HER2-positive stomach, esophageal, or other solid tumors that have spread or cannot be removed by surgery. The main goals are to find the safest dose and understand side …

This study tests whether adding enasidenib to the usual two-drug therapy (ASTX727 and venetoclax) can help more older adults with newly diagnosed IDH2-mutant acute myeloid leukemia (AML) achieve a deep remission. About 93 participants who are older or unfit for standard chemo wil…

This early-phase study tests a new treatment called TNhYP218 CAR T cells for people with solid tumors that have high levels of a protein called mesothelin, including mesothelioma. Participants' own immune cells are collected, modified in a lab to better attack cancer, and then gi…

This study tests whether combining two drugs, atezolizumab and selinexor, can shrink tumors in people with a rare cancer called alveolar soft part sarcoma (ASPS). About 27 adults with advanced or spreading ASPS will receive the combination. The goal is to see if this approach wor…

This study tests whether adding a new drug called PDS01ADC to standard radiation and hormone therapy can help the immune system fight prostate cancer better. About 65 men with intermediate- or high-risk prostate cancer that hasn't spread will take part. The goal is to find safe d…

This early-stage study tests a new drug called cirtuvivint, alone or with another drug (ASTX727), in people with certain blood cancers (MDS and AML) that have come back or not responded to treatment. The main goal is to find the safest dose and see what side effects occur. About …

This study looks at whether a simple blood test can find leftover cancer DNA after surgery for urinary tract cancers. About 992 people will be assigned to different immunotherapy plans based on their test results. The goal is to see if giving the drug nivolumab (alone or with rel…

This study tests whether a two-drug combination (enfortumab vedotin with or without pembrolizumab) can shrink or control rare cancers of the bladder, urinary tract, and testicles. About 68 adults with these uncommon tumors will receive the drugs through an IV for up to 5 years. T…

This early-phase study tests two experimental drugs, bintrafusp alfa and PDS01ADC, alone or with targeted radiation, in adults with metastatic bladder, kidney, or other non-prostate genitourinary cancers. The goal is to see if the combination is safe and can help the immune syste…

This study tests whether adding an immunotherapy drug (pembrolizumab) to standard chemotherapy (doxorubicin) helps people with certain advanced sarcomas live longer without their cancer growing. The trial includes about 365 adults whose sarcoma has spread or cannot be removed by …

This study tests a radioactive drug called lutetium Lu 177 dotatate in 30 people with a rare and aggressive form of prostate cancer that has spread. The drug seeks out and delivers radiation directly to cancer cells that have certain markers. The goal is to see if it can shrink t…

This early-phase trial tests the safety and best dose of a new targeted drug (SNDX-5613) when added to standard chemotherapy for adults with a specific type of acute myeloid leukemia (AML) that has changes in the NPM1 or MLL genes. The study enrolls 28 newly diagnosed patients ag…

This study tests whether a new radioactive tracer called 18F-fluciclovine can find multiple myeloma more accurately than the current tracer. About 60 adults with newly diagnosed or returning myeloma will get both types of PET/CT scans to compare them. The goal is to see if the ne…

This study tests whether a radioactive tracer called [68Ga]Ga-PentixaFor can help PET scans better identify adrenal tumors that release extra hormones. About 80 adults with high aldosterone or cortisol levels and known adrenal masses will receive one injection of the tracer and t…

This study tests whether a special PET scan using a radioactive tracer called 18F-DCFPyL can accurately show how prostate cancer responds to radiation therapy. About 130 adults with newly diagnosed, localized prostate cancer will get the scan before and after treatment. The goal …

This study tests whether a new imaging agent called [18F]FAPI-74 can find certain cancers as well as or better than the standard PET tracer. About 320 adults with one of 11 cancer types (including pancreatic, liver, ovarian, and lung cancers) will receive both tracers and have th…

This study compares HPV testing on self-collected vaginal samples versus samples collected by a doctor during a pelvic exam. About 500 women referred for colposcopy or cervical procedures will participate. The goal is to see if self-collection is accurate enough to increase scree…

This study tests whether a new drug, acolbifene, works better than a low dose of tamoxifen to prevent breast cancer in premenopausal women at high risk. Both drugs block estrogen, which can fuel breast cancer growth. About 80 women will take one of the two pills for six months, a…

This early-phase study tests the safety of a drug called ONC201 (dordaviprone) in 36 adults at high risk for colorectal cancer due to familial adenomatous polyposis (FAP) or a history of many polyps. The drug aims to kill precancerous cells without harming normal ones. Researcher…

This study tests whether adding high-dose omega-3 fatty acids to low-dose tamoxifen can better reduce breast cancer risk in overweight postmenopausal women who are already at higher risk. Tamoxifen blocks estrogen in breast tissue, while omega-3s may help with metabolism-related …

This study tests whether a broccoli seed and sprout extract can help heavy smokers break down and remove cancer-causing chemicals from tobacco. About 135 current smokers will take either the extract or a placebo daily for several weeks. Researchers will measure changes in urine l…

This study tests whether obeticholic acid can prevent Barrett's esophagus from progressing to esophageal cancer. Barrett's esophagus is a condition where the lining of the food pipe changes due to stomach acid and bile exposure, raising cancer risk. The drug works by reducing bil…

This study is for premenopausal women at higher-than-average risk for breast cancer. It tests whether a low dose of tamoxifen can safely reduce breast density, which is linked to cancer risk. About 200 women will take tamoxifen, and doctors will adjust the dose if needed to get t…

This study tests a device that sends mild electrical pulses to the pelvic floor muscles to help men who have bladder leakage after prostate cancer treatment. About 41 men with moderate leakage for at least 6 months will use the device at home for 20 minutes a day, 5 days a week, …

This study looks at whether Acceptance and Commitment Therapy (ACT) can help reduce stress for caregivers of children with a RASopathy, a group of genetic conditions. About 70 adult caregivers will take part in an 8-week online program that includes videos and coaching sessions. …

This study explores whether a normal camping experience can improve the emotional well-being of children with cancer. About 5,000 kids aged 7-17 who are currently in treatment or up to 5 years post-therapy will attend a 7-day camp. Researchers will interview families and observe …

This study gathers medical records and scan results from 10,000 men with prostate cancer or high risk for it. Researchers want to see how imaging features relate to the disease's behavior. The goal is to improve diagnosis and treatment planning, but no new treatments are given.

This study looks at how a stem cell transplant changes a person's DNA and how that affects drug dosing. Researchers will collect blood, skin, hair, and other samples from 88 adults before and after transplant. The goal is to find the best way to test a patient's genes for safe an…

This study collects tumor and healthy tissue samples from up to 2,415 people scheduled for surgery or biopsy for endocrine tumors (thyroid, parathyroid, adrenal, pancreas, or neuroendocrine). Researchers will analyze the samples to find genetic and molecular differences between b…

This study aims to collect blood, urine, tumor tissue, and fluid samples from up to 1,000 people with malignant mesothelioma or other cancers that express mesothelin. Participants will also be followed over time to track their disease and treatments. The samples will be stored an…

This study follows people with von Hippel-Lindau (VHL) disease who have pancreatic tumors or cysts. Researchers want to learn how these growths change over time and whether a special type of scan (68-Gallium DOTATATE PET/CT) can detect them better. Participants will have regular …

This study screens adults with cancers like melanoma, lung, or bladder cancer to see if they can join experimental treatments. Researchers take white blood cells from the patient's tumor or blood, grow them in a lab, and return them to fight the cancer. The goal is to find suitab…

This study follows up with people who previously received a gene therapy or immunotherapy vaccine (using poxviral vectors) for cancers like prostate, liver, breast, colon, or lung cancer. No new treatment is given. Participants get annual health checks for 5 years, then yearly ph…

This study is for people aged 3 and older with neurofibromatosis type 1 (NF1), a genetic condition that often causes noncancerous nerve tumors. About half of people with NF1 get these tumors, and sometimes they turn cancerous. Researchers want to test a new method to predict whic…

This study collects tumor and normal tissue samples from up to 1,800 people with solid tumors who are already scheduled for surgery or biopsy at the NIH Clinical Center. The samples are used to identify new molecular targets for cancer therapies. Participants also provide blood s…

This study collects blood and other samples from adults with cancer to learn how certain immune cells change before and after treatment. No treatment is given as part of this study. Up to 1,750 participants will provide samples, which researchers will analyze to better understand…

This study enrolls people with cancer who are already participating in other studies at the National Cancer Institute. Researchers will collect and link medical records and research samples from all of a person's past, current, and future studies. The goal is to better understand…

This long-term study aims to uncover the causes of cancer by following 200,000 adults aged 30–70 who have never had cancer. Participants complete online surveys, donate blood, urine, and saliva every few years, and share their electronic health records. The goal is to learn how l…

This study aims to better understand rare solid tumors by collecting biological samples (like blood, saliva, and tumor tissue) and health information from up to 10,000 people over many years. Participants include people with a rare tumor, those with a genetic risk for one, and th…

This study collects white blood cells from healthy volunteers to help researchers develop new cancer treatments that use a person's own immune system. Participants undergo a 4-6 hour procedure called apheresis to donate cells. The cells are used only for laboratory research, not …

This study follows 300 people aged 30 and older who have or may have a BAP1 gene mutation, which raises the risk of mesothelioma and other cancers. Researchers will use advanced CT scans, blood and urine tests, and minimally invasive camera procedures to find cancers as early as …

This study aims to learn how genes and environmental factors cause rare tumors and cancer in individuals and families. Up to 500 people of any age with unusual cancers, a family history of cancer, or certain exposures may join. Participants provide medical history, samples, and e…

This study follows people with inherited BAP1 gene mutations, which raise the risk of mesothelioma and other cancers. Researchers want to learn how these cancers develop over time. Participants may join in person or remotely, providing medical history, saliva, and tumor samples. …

This study collects blood samples from 1,000 men with prostate cancer to look for genetic differences that may explain why some cancers stop responding to hormone therapy. Participants give blood at clinic visits, and researchers analyze DNA and other genetic material. The goal i…

This study follows people with a gene change (DDX41) that raises their risk for blood cancers like MDS and AML, along with their relatives. Researchers will collect health updates, blood samples, and medical records for up to 10 years to learn how the gene affects cancer developm…

This study collects tissue and fluid samples from up to 5,000 cancer patients to help researchers learn more about cancer and develop new tests and treatments. Samples are taken from routine procedures or from extra biopsies done just for research. The goal is to build a resource…

This study collects blood, urine, saliva, and tumor tissue from 500 adults with or at risk for urothelial cancer (bladder, ureter, urethra). Researchers will analyze DNA and other molecular changes to understand what causes the cancer and how it responds to treatment. Participant…

This study screens up to 2,900 people with advanced or hard-to-treat solid tumors to find genetic changes in their cancer cells. Based on those results, patients may be matched to a treatment trial that uses a combination of drugs targeting their specific mutations. The goal is t…

This study follows up to 2,000 men with prostate cancer who have certain gene mutations. Researchers want to understand how these genes affect the way the cancer grows, spreads, and responds to treatment. Participants are followed for life through phone calls, emails, and medical…

This study follows up to 4,000 people with inherited bone marrow failure syndromes (like Fanconi anemia) and their families to learn why they get certain cancers. Researchers will track health over time, collect samples, and compare those who develop cancer with those who don't. …

This study is testing whether frequent blood and bone marrow tests can help doctors know which children with B-cell acute lymphoblastic leukemia (B-ALL) are cured by CAR T-cell therapy alone and which might need a stem cell transplant. About 60 participants aged 1 to 25 who have …

This study aims to learn more about Li-Fraumeni syndrome (LFS), a genetic condition that raises the risk of several cancers. Researchers will study up to 5,000 people with LFS or related cancer histories to find new genes, understand how the TP53 gene works, and identify factors …

This study is creating a registry of very rare solid tumors in people aged 1 month to 39 years. Researchers will collect medical records, tumor samples, and survey answers from participants over 5 years. No clinic visits are needed; participation is by phone or mail. The goal is …

This study aims to collect blood, tissue, and bone marrow samples from 200 adults with untreated follicular lymphoma. Researchers will monitor participants every 4 months for up to 2 years, then every 6 months for 5 years, to see how the cancer changes and responds to treatment. …

This study examines DNA from 575 breast cancer patients who received the chemotherapy drug paclitaxel. Researchers want to find genetic differences that explain why some patients develop nerve damage (peripheral neuropathy) while others do not. The goal is to identify biomarkers …

This study is testing a new technology called SmartMatch that analyzes tumor tissue from people with recurrent brain or spinal cord tumors. The goal is to see if SmartMatch can quickly identify which drugs might work best for each person's specific tumor. About 80 participants ag…

This study aims to create a large collection of tissue samples from people with head and neck disorders, such as hearing loss, mouth diseases, and throat cancer. Researchers will use leftover tissue from medical procedures and collect additional samples like blood, saliva, and ch…

This study aims to collect and store extra blood, tissue, urine, and tumor samples from children and adults diagnosed with childhood cancers like leukemia, sarcoma, and neuroblastoma. The samples are taken only when already needed for medical care, so no extra procedures are requ…

This study aims to understand where HIV hides in the body when people stop their daily medication for a short time. About 50 adults with HIV will either stay on their regular treatment or pause it for up to 90 days. Researchers will use scans and tissue samples to measure virus l…

This study aims to learn more about myelodysplastic syndromes (MDS) by following people with the condition for up to 20 years. Researchers will collect blood, bone marrow, and other samples to better understand how MDS progresses. Up to 1,100 participants, including healthy donor…

This study follows children and adults with medullary thyroid cancer (MTC) and related genetic conditions (MEN2A or MEN2B) to learn how the disease progresses over time. Participants receive no experimental treatment but undergo regular check-ups, blood tests, and imaging every 6…

This study follows 500 men aged 30-75 who have specific gene changes linked to prostate cancer but have not been diagnosed yet. Researchers will track their health over time using yearly checkups, blood tests, and MRI scans to learn how these genetic risks affect prostate cancer …

This study uses detailed MRI scans and biopsies to learn why some men's prostate cancer returns after radiation treatment. About 300 men with intermediate or high-risk prostate cancer, or whose cancer has come back after earlier treatments, will be followed for years. The goal is…

This study collects blood, urine, bone marrow, and tissue samples from adults with lymphoid cancers or precancerous conditions. The goal is to help researchers better understand these diseases and potentially find new ways to diagnose or treat them. No treatment is provided as pa…

This study aims to better understand inherited forms of kidney and other urinary tract cancers. Researchers will follow up to 5,000 people with a known or suspected genetic risk to track how the disease develops over time and identify the specific genes involved. The goal is to i…

This study collects blood and tumor tissue from adults with gastrointestinal cancers (throat, stomach, gallbladder, liver, pancreas, or colon) to learn how the immune system responds to cancer. Participants give blood samples over several months and may provide tumor tissue if th…

This study follows people with Fanconi anemia, a rare inherited condition that raises the risk of certain cancers, especially squamous cell carcinoma. Researchers will screen 200 participants aged 12 and older every year for up to 10 years using exams, blood tests, and imaging to…

This study collects tissue and blood samples from 280 adults with HIV, viral-associated cancers, or Castleman disease to analyze their genes. Researchers compare cancer tissue genes to normal tissue genes to find variations that may affect cancer development. The goal is to bette…

This study collects blood, bone marrow, skin, saliva, and stool samples from 1,000 healthy adults aged 18 and older. The samples are used as a comparison to better understand myelodysplastic syndromes (MDS), a group of blood disorders that can lead to cancer. Participants do not …

This study aims to learn more about KSHV inflammatory cytokine syndrome (KICS), a newly recognized illness caused by a virus that can also lead to certain cancers. Researchers will collect medical history, blood samples, and imaging from 140 adults with KICS to understand how the…

This study screens 2000 adults with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome. It tests their blood and bone marrow for specific markers to quickly match them with a targeted treatment trial or standard care. The goal is to see if this matching process ca…

This study follows 650 people with chronic graft-versus-host disease (cGVHD), a complication after stem cell transplants. Researchers aim to track the disease over time, identify biological markers, and improve how it is diagnosed and managed. Participants undergo regular check-u…

This study follows people with common and rare urinary tract cancers (like bladder, kidney, and testicular) to understand how these cancers behave over time. Researchers will collect medical records, blood, urine, and tumor samples to track disease progression and treatment respo…

This study looks at whether having guided conversations about care preferences helps young adults (ages 18-39) who are about to receive a stem cell transplant, along with their caregivers. Participants will fill out questionnaires and have three talks with a study team member ove…

This study looks at DNA from 354 breast cancer patients to find genetic differences that may cause high blood pressure as a side effect of the drug bevacizumab. Researchers will compare patients who developed severe hypertension with those who did not. The goal is to identify bio…

This study follows 150 adults with Kaposi sarcoma (KS), a tumor caused by a virus, to learn how the disease starts, changes, and may come back. Participants will have regular check-ups, scans, and biopsies over up to 10 years. The goal is to better understand KS, not to test a ne…

This study examines DNA from 162 breast cancer patients who received chemotherapy and either did or did not develop congestive heart failure. Researchers want to find specific gene changes that might increase the risk of heart problems after treatment. The goal is to better under…

This study looks at whether advanced MRI scans can help doctors better monitor prostate cancer in men who choose active surveillance (watching the cancer instead of treating it right away). About 500 men with low- or intermediate-risk prostate cancer will get regular MRIs alongsi…

This study follows people who have had a stem cell transplant (and their donors) for many years after the procedure. Researchers want to understand the long-term effects, how the transplanted cells change, and how to better fight cancer. Participants include adults and children w…

This study aims to see if lab-grown tumor models can predict how well heated chemotherapy (HIPEC) works during surgery for cancers that have spread to the abdomen. About 60 adults will have their tumors removed, then some are tested in the lab while others receive the actual heat…

This study is for people who have or are at risk for rare tumors linked to changes in the DICER1 gene, and their close relatives. Researchers will collect medical history, genetic samples, and track health over time to better understand the condition. No treatment is provided, bu…

This study follows up to 700 people who have already received radiation therapy for cancer. The goal is to collect information over time about late side effects and how the disease progresses. No new treatments are given; researchers simply gather data from standard follow-up car…

This study looks at whether a device that measures pupil changes can help assess pain and other unusual sensations in people with NF1, a genetic condition that causes nerve tumors. About 70 people aged 1 and older with NF1 will have a small electrode placed on a finger or toe to …

This study tests a redesigned surgical tool for removing bladder tumors. The goal is to see if it gives doctors better information about the tumor, such as whether all layers are removed and if cancer cells remain at the edges. About 25 adults who need their bladder removed will …

This study is testing new blood tests that look for signs of many different cancers at the same time. Researchers want to see if these tests can find cancer early, when treatment works best. About 24,000 adults aged 45 to 75 who do not have cancer will be randomly placed into one…

This study collects blood, bone marrow, tumor, and tissue samples from adults with HIV, KSHV, or certain cancers. The goal is to gather samples for research, not to provide treatment. Up to 999 participants will donate samples over time to help scientists learn more about these d…

This study follows people with KSHV-associated multicentric Castleman disease (MCD) to learn how the illness progresses and responds to standard treatments. Researchers will collect medical history, scans, and samples over several years. The goal is to better understand the disea…

This study looks at anxiety caused by regular cancer screenings in adults with Fanconi Anemia, a rare inherited condition that raises cancer risk. Researchers will observe 20 participants during their clinic visits, noting body language, worries, and the clinic environment. No tr…

This study collects blood, urine, bone marrow, and tumor samples from people with hairy cell leukemia and other blood cancers, as well as from healthy volunteers. Researchers will use these samples to study the diseases and develop new treatments called immunotoxins, which use an…

This study collects blood, bone marrow, and tumor samples from 500 adults with cancer or pre-cancerous conditions. Researchers will use these samples to learn more about how cancer works and why some cancers respond differently to treatment. The goal is to develop more effective …

This study collects blood, urine, saliva, and tissue samples from people who have or may have cancer, as well as their relatives. The samples are stored and used by researchers to study the genetic and molecular causes of cancer. The goal is to better understand the disease, not …

This study collects blood or cheek swab samples from 1,100 people with cancer who are already in an NCI treatment trial. The goal is to find genetic differences that might affect how well a treatment works or how likely side effects are. Participants must be at least 3 years old …

This study aims to learn more about RASopathies, a group of genetic conditions that can cause developmental issues, birth defects, and increased cancer risk. Researchers will follow up to 500 people of any age who have or may have a RASopathy, along with their family members, for…

This study collects tumor tissue, blood, and other samples from 2,000 adults with certain lung and thymic cancers. Researchers will use these samples to learn more about how these cancers grow and change over time. The goal is to find new ways to diagnose and treat these diseases…

This study collects blood stem cells from people with DOCK8 deficiency, LAD-1, or GATA2 deficiency to test gene therapy in the lab. Participants receive daily injections to move stem cells into the blood, then donate cells through a procedure called apheresis. The cells are used …

This study aims to find the genetic changes that cause hereditary leiomyomatosis renal cell cancer (HLRCC), a condition that can lead to kidney tumors, painful skin bumps, and uterine fibroids. Researchers will study people with known or suspected HLRCC and their family members t…

This study follows 300 people aged 2 and older with chordoma, a rare bone cancer of the skull base or spine. Researchers will track how the disease progresses using imaging scans, physical exams, and surveys. The goal is to better understand chordoma's natural history to design i…

This study collects blood, urine, saliva, and tumor tissue from men with or suspected to have prostate cancer. Researchers will analyze these samples to find genetic changes that cause the disease to develop and spread. The goal is to better understand prostate cancer and pave th…

This study aims to collect tumor tissue, normal tissue, and blood samples from up to 1,559 people with cancers of the lung, esophagus, or chest lining. Researchers will analyze these samples to learn about genetic and epigenetic changes that may affect how the disease progresses.…

This study is for people aged 8 and older with neurofibromatosis type 1 (NF1) who have visible tumors, and for caregivers of children with NF1. Researchers want to see if two questionnaires can better measure how tumors affect appearance and quality of life. Participants will joi…

This study follows 400 people aged 6 and older with gastrointestinal stromal tumors (GISTs) to collect tumor tissue and blood samples for research. Participants are monitored every 6-12 months for up to 10 years before surgery, and for 5 years after. The goal is to better underst…

This study looks at how genes and the environment affect the risk of melanoma, a serious skin cancer. Researchers will enroll up to 3,000 people with a personal or family history of melanoma. Participants fill out questionnaires, give blood or cheek cell samples, and may have ski…

This study aims to learn more about Birt-Hogg-Dube (BHD) syndrome, a rare inherited condition that raises the risk of kidney cancer. Researchers will study up to 950 people with known or suspected BHD and their family members to find the genetic changes responsible and understand…

This study aims to collect tissue samples and health information from 300 adults with neuroendocrine neoplasms (NENs), including adrenocortical carcinoma. Researchers will follow participants over time to understand how these rare cancers grow and respond to treatments. The goal …

This study works to improve questionnaires that measure pain, daily activities, and physical function for people with neurofibromatosis type 1 (NF1) who have plexiform neurofibromas. Participants aged 5 and older will give feedback on existing surveys through group discussions or…

This study aims to understand if CAR T-cell therapy, a treatment for blood cancers like leukemia and lymphoma, can affect thinking skills such as memory and attention in children and young adults aged 5 to 35. Participants will take thinking tests and answer questions at home or …

This study aims to better understand olfactory neuroblastoma, a rare cancer of the nasal cavity. Researchers will follow 525 people aged 3 and older, collecting medical records, blood samples, and smell tests over their lifetime. The goal is to learn how the disease progresses an…

This study is testing whether a special PET/CT scan using a radioactive tracer called 18F-DCFPyL can find prostate cancer that has come back after initial treatment. About 350 men whose cancer has returned will get this scan regularly for up to 5 years. The goal is to see how wel…

This study is developing a new questionnaire to better understand and measure symptoms in children and teens living with chronic graft-versus-host disease (cGVHD), a common side effect after a stem cell transplant. Researchers will work with children aged 5-17 and their parents t…

This study looks at whether measuring two proteins (VEGF and MMP) in blood and urine can help predict if a glioblastoma brain tumor will come back within a year after radiation therapy. About 200 adults with this type of brain tumor will provide samples before, during, and after …